Gene: SUZ12
Official Full Name: SUZ12 polycomb repressive complex 2 subunitprovided by HGNC
Gene Summary: This zinc finger gene has been identified at the breakpoints of a recurrent chromosomal translocation reported in endometrial stromal sarcoma. Recombination of these breakpoints results in the fusion of this gene and JAZF1. The protein encoded by this gene contains a zinc finger domain in the C terminus of the coding region. [provided by RefSeq, Jul 2009]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO04241 | SUZ12 Knockout cell line (HeLa) | Human | SUZ12 | 1:3~1:6 | Negative | Online Inquiry |
KO04242 | SUZ12 Knockout cell line (HCT 116) | Human | SUZ12 | 1:2~1:4 | Negative | Online Inquiry |
KO04243 | SUZ12 Knockout cell line (HEK293) | Human | SUZ12 | 1:3~1:6 | Negative | Online Inquiry |
KO04244 | SUZ12 Knockout cell line (A549) | Human | SUZ12 | 1:3~1:4 | Negative | Online Inquiry |
SUZ12 Gene Knockout Cell Lines are genetically modified cells specifically designed to have a non-functional SUZ12 gene, which plays a critical role in the regulation of gene expression through its involvement in polycomb repressive complexes (PRCs). This modification highlights the importance of SUZ12 in cellular processes such as proliferation, differentiation, and development by allowing researchers to study the specific impacts of its absence.
The key function of these knockout cell lines lies in their ability to provide insights into the role of SUZ12 in various biological contexts. By utilizing the CRISPR-Cas9 technology or other gene-editing techniques, researchers can effectively investigate the downstream consequences of SUZ12 loss on gene expression patterns, chromatin remodeling, and cellular pathways. Such experiments can elucidate the mechanisms by which SUZ12 contributes to tumorigenesis, epigenetic regulation, and stem cell fate determination, providing valuable information in both basic and applied research settings.
Interestingly, SUZ12 gene knockout cell lines are of significant importance in translational research and are sought after in clinical investigations aimed at cancer therapy development. These cell lines serve as powerful models for drug screening and validation, as they showcase altered cellular responses to therapeutic agents, enabling the identification of novel treatment strategies targeting SUZ12-associated pathways.
One of the distinctive advantages of our SUZ12 Gene Knockout Cell Lines is their reliability and reproducibility, coupled with comprehensive characterization data that ensures researchers have access to high-quality cell models. Furthermore, these lines are meticulously validated for specific genetic alterations, which sets them apart from alternative products that may lack stringent quality control measures.
For researchers and clinicians, these cell lines represent an invaluable tool to unlock the mysteries of gene regulation and its implications in disease states. Their ability to mimic disease conditions while allowing controlled experimental manipulations is crucial for advancing scientific knowledge and therapeutic options.
Our company is committed to providing cutting-edge biological products, backed by a team of dedicated scientists and decades of expertise in genetic engineering and cell line development. We ensure that every product showcases the highest standards of quality and innovation, empowering researchers and clinicians to make meaningful advancements in their fields.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.